| Literature DB >> 24949476 |
Heng-Zhu Zhang1, Yu-Ping Li1, Zheng-cun Yan1, Xing-dong Wang1, Lei She1, Xiao-dong Wang1, Lun Dong1.
Abstract
Neuroendoscopic (NE) surgery as a minimal invasive treatment for basal ganglia hemorrhage is a promising approach. The present study aims to evaluate the efficacy and safety of NE approach using an adjustable cannula to treat basal ganglia hemorrhage. In this study, we analysed the clinical and radiographic outcomes between NE group (21 cases) and craniotomy group (30 cases). The results indicated that NE surgery might be an effective and safe approach for basal ganglia haemorrhage, and it is also suggested that NE approach may improve good functional recovery. However, NE approach only suits the selected patient, and the usefulness of NE approach needs further randomized controlled trials (RCTs) to evaluate.Entities:
Mesh:
Year: 2014 PMID: 24949476 PMCID: PMC4052154 DOI: 10.1155/2014/898762
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Photograph of an adjustable cannula with metal stylet.
Figure 2The CT scan results of illustrative case. (a) The CT scan showed preoperational volume of hematoma. (b) The CT scan revealed hematoma volume 24 hours after surgery.
Figure 3Using adjustable cannula in neuroendoscopic surgery. (a) A 4 cm long linear skin incision is shown and 2.5 cm keyhole craniotomy in diameter was used in patient. (b) The suction unit was applied to evacuate hematoma. (c) The bipolar coagulator hemostasis was applied in bleeding vessels.
Clinical characteristics of included patients between NE group and the traditional craniotomy group.
| NE group | Craniotomy group |
| |
|---|---|---|---|
| Cases ( | 21 | 30 | — |
| Male/female ( | 16/5 | 22/8 | 0.82 |
| Age (years) | 59.90 ± 12.85 | 61.45 ± 9.25 | 0.64 |
| Preoperation hematoma volume (mL) | 58.28 ± 18.84 | 62.16 ± 15.62 | 0.44 |
| GCS score | 9.19 ± 3.76 | 8.37 ± 2.39 | 0.38 |
| mRS score | 3.57 ± 1.66 | 3.88 ± 2.14 | 0.56 |
| History of hypertension ( | 15/76.19% | 23/73.33% | 0.67 |
| Time between symptom onset and surgery, 12 h | 9 | 10 | 0.89 |
P < 0.05 showing statistically significant differences.
Clinical findings and functional outcomes in included patients.
| Variable | NE group | Craniotomy group |
| |
|---|---|---|---|---|
| Hematoma evacuation rate (%) | 90.11 ± 7.27 | 85.37 ± 6.78 | 0.02* | |
| Operating time (min) | 76.48 ± 14.92 | 175.15 ± 26.13 | <0.00001* | |
| Mortality ( | — | 3/10.0 | 0.27 | |
| Rebleeding rate ( | 1/4.76 | 3/10.0 | 0.50 | |
| Infection rate ( | 2/9.52 | 11/36.67 | 0.04* | |
| Mean GOS score | 6th month | 3.61 ± 0.92 | 3.05 ± 1.26 | 0.07 |
| Mean mRS score | Discharge | 2.85 ± 1.88 | 2.96 ± 1.65 | 0.83 |
| 6th month | 2.33 ± 1.83 | 2.67 ± 1.54 | 0.49 | |
| Mean GCS score | 3 days after surgery | 9.71 ± 2.64 | 9.03 ± 2.85 | 0.38 |
| Discharge | 11.61 ± 2.87 | 10.25 ± 2.45 | 0.08 | |
| Good functional outcome ( | 11/52.38 | 4/13.33 | 0.04* | |
| NICU (d) | 6.5 | 11.2 | 0.005* |
*P < 0.05 showing statistically significant difference.
Good functional outcome (GFO) is defined as a patient being able to care for him/herself, corresponding to a modified Rankin Scale (mRS) of 0, 1, 2, or 3, a Glasgow Outcome Scale (GOS) of 4 or 5, or activities of daily living (ADL) score [14] of 1, 2, or 3.